Alnylam Pharmaceuticals is set to publish its earnings report, with some expecting negative earnings which may affect its stock price. Various investment groups, including abrdn plc, Chicago Partners, and Strategic Financial Concepts have adjusted their holdings, with some reducing and others increasing their investments significantly. An analysis shows a promising outlook for Alnylam regarding its ATTR-CM stock. Alnylam's 2024 financial results, a key detail for bio-tech investors, is seen as crucial. In addition, they have submitted an application for Vutrisiran's treatment of ATTR Amyloidosis with Cardiomyopathy to both the U.S FDA and European Medicines Agency. Alnylam's successful trial results have made them a leading biotech performer in 2024. New advancements, including the phase 1 data of Nucresiran, show sustained rapid knockdown of TTR at six months after a single dose. The company's stock position is increasing amongst multiple investors, despite insider sales suggesting hesitancy. The firm's firming portfolio showcases a strong commitment to advancing RNAi (RNA interference) therapeutics.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 08 Feb 2025 10:13:01 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor -7
